Abstract
The Nobel Prize for Medicine and Physiology in 1998 to Furchgott, Ignarro, and Murad provided a new impetus to research in prodrugs of the messenger molecule, nitric oxide (NO). Although more famously known for its cardiovascular roles in the treatment of angina (nitrates) and more recently erectile dysfunction (Viagra®), NO has been extensively researched within the realm of cancer biology. This review briefly highlights the various chemical classes of NO donors with potential utility in cancer chemotherapy and chemoprevention. These molecules release NO upon bioactivation and thus engender the therapeutic rationale of using them in a clinical setting. Bearing these factors in mind, and in the light of current research findings, special emphasis is given to a newer generation of NORMs (nitric oxide-releasing molecules), viz., NONOates, NO-NSAIDs, and furoxans.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Al-Kaabi, S.S., Williams, D.L.H., Bonnett, R., and Ooi, S.L. (1982). A kinetic investigation of the thionitrite from (±)-2-acetylamino-2-carboxy-1,1-dimethylethanethiol as a possible nitrosating agent. J. Chem. Soc. Perkin Trans. 2, 227–230.
Albert, A. (1958). Chemical aspects of selective toxicity. Nature 182, 421–423.
Alston, T.A., Porter, D.J., and Bright, H.J. (1985). Generation of nitric oxide by enzymatic oxidation of N-hydroxy-N-nitrosamines. J. Biol. Chem. 260, 4069–4074.
Armstrong, R.N. (1991). Glutathione S-transferases: Reaction mechanism, structure, and function. Chem. Res. Toxicol. 4, 131–140.
Armstrong, R.N. (1997). Structure, catalytic mechanism, and evolution of the glutathione transferases. Chem. Res. Toxicol. 10, 2–18.
Balbo, S., Lazzarato, L., Di Stilo, A., Fruttero, R., Lombaert, N., and Kirsch-Volders, M. (2008). Studies of the potential genotoxic effects of furoxans: The case of Cas 1609 and of the water-soluble analogue of Chf 2363. Toxicol. Lett. 178, 44–51.
Baldwin, J.J. (1987). Drug design, drug discovery development In Williams, M., and Malick, J.B. (ed.). (p. 447). Clifton, NJ, Humana Press.
Becker, J.C., Domschke, W., and Pohle, T. (2004). Current approaches to prevent Nsaid-Induced gastropathy – Cox selectivity and beyond. Br. J. Clin. Pharmacol. 58, 587–600.
Bell, G.I., Burant, C.F., Takeka, J., and Gould, G.W. (1993). Structure and Function of Mammalian Facilitative Sugar Transporters. J. Biol. Chem. 268, 19161–19164.
Bennett, A., Tacca, M.D., Stamford, I.F., and Zebro, T. (1977). Prostaglandins from tumours of human large bowel. Br. J. Cancer. 35, 881–884.
Bohn, H., Brendel, J., Martorana, P.A., and Schönafinger, K. (1995). Cardiovascular actions of the furoxan cas 1609, a Novel nitric oxide donor. Br. J. Pharmacol. 114, 1605–1612.
Boiani, M., Cerecetto, H., González, M., Risso, M., Olea-Azar, C., Piro, O.E., Castellano, E.E., López de Ceráin, A., Ezpeleta, O., and Monge-Vega, A. (2001). 1, 2, 5-Oxadiazole N-oxide derivatives as potential anti-cancer agents: Synthesis and biological evaluation. Part Iv. Eur. J. Med. Chem. 36, 771–782.
Bolla, M., Almirante, N., and Benedini, F. (2005). Therapeutic potential of nitrate esters of commonly used drugs. Curr. Top. Med. Chem. 5, 707–720.
Brzozowska, I., Targosz, A., Sliwowski, Z., Drozdowicz, S.K.D., Pajdo, R., Konturek, P.C., Brzozowski, T., Pawlik, M., Konturek, S.J., Pawlik, W.W., and Hahn, E.G. (2004). Healing of chronic gastric ulcers in diabetic rats treated with native aspirin, nitric oxide (No)-derivative of aspirin and cyclooxygenase (Cox)-2 inhibitor. J. Physiol. Pharmacol. 55, 773–790.
Buonsanti, M.F., Bertinaria, M., Di Stilo, A., Cena, C., Fruttero, R., and Gasco, A. (2007). Nitric oxide donor B2-agonists: Furoxan derivatives containing the fenoterol moiety and related furazans. J. Med. Chem. 50, 5003–5011.
Burgaud, J.L., Ongini, E., and del Soldato, P. (2002a). Nitric oxide-releasing drugs. Ann. N. Y. Acad. Sci. 962, 360–371.
Burgaud, J.L., Riffaud, J.P., and Soldato, P. (2002b). Nitric-oxide releasing molecules: A new class of drugs with several major indications. Curr. Pharm. Des. 8, 201–213.
Cai, T.B., Tang, X., Nagorski, J., Brauschweiger, P.G., and Wang, P.G. (2003). Synthesis and cytotoxicity of 5-fluorouracil/diazeniumdiolate conjugates. Bioorg. Med. Chem. 11, 4971–4975.
Calvino, R., Mortarini, V., Gasco, A., and Sanfilippo, A. (1980). Antimicrobial properties of some furazan and furoxan derivatives. Eur. J. Med. Chem. 15, 485–487.
Cerecetto, H., Di Maio, R., Gonzalez, M., Risso, M., Saenz, P., Seoane, G., Denicola, A., Peluffo, G., Quijano, C. and Olea-Azar, C. (1999). 1, 2, 5-Oxadiazole N-Oxide Derivatives and related compounds as potential antitrypanosomal drugs: structure-activity relationships. J. Med. Chem. 42, 1941–1950.
Cerecetto, H. and González, M. (2007). Benzofuroxan and furoxan. chemistry and biology, bioactive heterocycles Iv (ed.) (Vol. 10, pp. 265–308) Springer Berlin/Heidelberg.
Cerecetto, H., González, M., Risso, M., Seoane, G., Ceráin, A.L. d., Ezpeleta, O., Monge, A., Suescun, L., Mombrú, A., and Bruno, A.M. (2000). Synthesis and biological evaluation of 1, 2, 5-oxadiazole N-oxide derivatives as potential hypoxic cytotoxins and DNA-binders. Arch. Pharm. (Weinheim) 333, 387–393.
Chaiswing, L., Zhong, W., Cullen, J.J., Oberley, L.W., and Oberley, T.D. (2008). Extracellular redox state regulates features associated with prostate cancer cell invasion. Cancer Research 68, 5820–5826.
Chakrapani, H., Bartberger, M.D., and Toone, E.J. (2009). C-nitroso donors of nitric oxide. J. Org. Chem. 74, 1450–1453.
Chen, L., Zhang, Y., Kong, X., Lan, E., Huang, Z., Peng, S., Kaufman, D.L., and Tian, J. (2008). Design, synthesis, and antihepatocellular carcinoma activity of nitric oxide releasing derivatives of oleanolic acid. J. Med. Chem. 51, 4834–4838.
Christiaans, J.A.M. and Timmerman, H. (1996). Cardiovascular hybrid drugs: Combination of more than one pharmacological property in one single molecule. Eur. J. Pharm. Sci. 4, 1–22.
Civelli, M., Giossi, M., Caruso, P., Razzetti, R., Bergamaschi, M., Bongrani, S., and Gasco, A. (1996). The involvement of the release of nitric oxide in the pharmacological activity of the new furoxan derivative Chf 2363. Br. J. Pharmacol. 118, 923–928.
Davies, N.M., Røseth, A.G., Appleyard, C.B., McKnight, W., Soldato, P.D., Calignano, A., Cirino, G., and Wallace, J.L. (1997). No-naproxen vs. naproxen: Ulcerogenic, analgesic and anti-inflammatory effects. Aliment. Pharmacol. Ther. 11, 69–79.
Di Napoli, M. and Papa, F. (2003). Ncx-4016 Nicox. Curr. Opin. Investig. Drugs 4, 1126–1139.
Dunlap, T., Abdul-Hay, S.O., Chandrasena, R.E.P., Hagos, G.K., Sinha, V., Wang, Z., Wang, H., and Thatcher, G.R.J. (2008). Nitrates and No-nsaids in cancer chemoprevention and therapy: In Vitro evidence querying the no donor functionality. Nitric Oxide 19, 115–124.
Dunlap, T., Chandrasena, R.E.P., Wang, Z., Sinha, V., Wang, Z., and Thatcher, G.R.J. (2007). Quinone formation as a chemoprevention strategy for hybrid drugs: Balancing cytotoxicity and cytoprotection. Chem. Res. Toxicol. 20, 1903–1912.
Fabbri, F., Brigliadori, G., Ulivi, P., Tesei, A., Vannini, I., Rosetti, M., Bravaccini, S., Amadori, D., Bolla, M., and Zoli, W. (2005). Pro-apoptotic effect of a nitric oxide-donating Nsaid, Ncx 4040, on bladder carcinoma cells. Apoptosis 10, 1095–1103.
Feelisch, M., Schönafingeri, K., and Noack, H. (1992). Thiol-mediated generation of nitric oxide Accounts for the vasodilator action of furoxans. Biochem. Pharmacol. 44, 1149–1157.
Ferioli, R., Folco, G.C., Ferretti, C., Gasco, A.M., Medana, C., Fruttero, R., Civelli, M., and Gasco, A. (1995). A new class of furoxan derivatives as no donors: Mechanism of action and biological activity. Br. J. Pharmacol. 114, 816–820.
Findlay, V.J., Townsend, D.M., Saavedra, J.E., Buzard, G.S., Citro, M.L., Keefer, L.K., Ji, X., and Tew, K.D. (2004). Tumor cell responses to a novel glutathione S-transferase-activated nitric oxide-releasing prodrug. Mol. Pharmacol. 65, 1070–1079.
Fiorucci, S., Santucci, L., Cirino, G., Mencarelli, A., Familiari, L., Soldato, P.D., and Morelli, A. (2000). Il-1b converting enzyme is a target for nitric oxide-releasing aspirin: New insights in the antiinflammatory mechanism of nitric oxide-releasing nonsteroidal antiinflammatory drugs. J. Immunol. 165, 5245–5254.
Fruttero, R., Ferrarotti, B., Serafino, A., Di Stilo, A., and Gasco, A. (1989). Unsymmetrically substituted furoxans. Part 11. Methylfuroxancarbaldehydes. J. Het. Chem. 26, 1345–1347.
Furchgott, R.F. (1999). Endothelium-derived relaxing factor: Discovery, early studies, and identification as nitric oxide (Nobel Lecture). Angew. Chem. Intd. Ed. 38, 1870–1880.
Gasco, A., Fruttero, R., Sorba, G., Stilo, A.D., and Calvino, R. (2004). No donors: Focus on furoxan derivatives. Pure Appl. Chem. 76, 973–981.
Ghosh, P., Ternai, B., and Whitehouse, M. (1981). Benzofurazans and Benzofuroxans: biochemical and pharmacological properties. Med. Res. Rev. 1, 159–187.
Ghosh, P.B. and Whitehouse, M.W. (1968). Potential antileukemic and immunosuppressive drugs. Preparation and in vitro pharmacological activity of some 2, 1, 3-benzoxadiazoles (benzofurazans) and their N-oxides (benzofuroxans). J. Med. Chem. 11, 305–311.
Gooden, D.M., Chakrapani, H., and Toone, E.J. (2005). C-nitroso compounds: synthesis, physicochemical properties and biological activities. Curr. Top. Med. Chem. 5, 687–705.
Govoni, M., Casagrande, S., Maucci, R., Chiroli, V., and Tocchetti, P. (2006). In vitro metabolism of (Nitrooxy)butyl ester nitric oxide-releasing compounds: Comparison with glyceryl trinitrate. J. Pharmacol. Exp. Ther. 317, 752–761.
Greene, F.D. and Gilbert, K.E. (1975). Cyclic azo dioxides. Preparation, properties, and consideration of azo dioxide-nitrosoalkane equilibriums. J. Org. Chem. 40, 1409–1415.
Guo, Z., Ramirez, J., Li, J., and Wang, P.G. (1998). Peptidyl N-nitrosoanilines: A novel class of cysteine protease inactivators. J. Am. Chem. Soc. 120, 3726–3734.
Guo, Z., Xian, M., Zhang, W., McGill, A., and Wang, P.G. (2001). N-nitrosoanilines: A new class of caspase-3 inhibitors. Bioorg. Med. Chem. 9, 99–106.
Hagos, G.K., Abdul-Hay, S.O., Sohn, J., Edirisinghe, P.D., Chandrasena, R.E.P., Wang, Z., Li, Q., and Thatcher, G.R.J. (2008). Anti-inflammatory, antiproliferative, and cytoprotective activity of no chimera nitrates of use in cancer chemoprevention. Mol. Pharmacol. 74, 1381–1391.
Hou, Y., Wang, J.-Q., Andreana, P.R., Cantaurea, G., Tarasia, S., Sharp, L., Brauschweiger, P.G., and Wang, P.G. (1999a). Targeting nitric oxide to cancer cells: Cytotoxicity studies of glyco-S-nitrosothiols. Bioorg. Med. Chem. Lett. 9, 2255–2258.
Hou, Y., Wang, J.-Q., Ramirez, J., Wang, P.G. (1999b). Glyco-S-Nitrosothiols: sugar-snap, a new type of nitric oxide donor, methods in Enzymology: In Packer, L. (ed.), Nitric oxide part C: biological and antioxidant activities. Academic, San Diego, CA. 301, 242–249.
Hou, Y., Xie, W., Janczuk, A.J., and Wang, P.G. (2000a). O-alkylation of cupferron:aiming at the design and synthesis of controlled nitric oxide releasing agents. J. Org. Chem. 6, 4333–4337.
Hou, Y., Xie, W., Ramachandran, N., Mutus, B., Janczuk, A.J., and Wang, P.G. (2000b). O-alkylation chemistry of neocupferron. Tet. Lett. 41, 451–456.
Hrabie, J.A. and Keefer, L.K. (1999). Preparation of novel nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates as drugs. USPTO. United States of America: 59.
Hrabie, J.A. and Keefer, L.K. (2002). Chemistry of the nitric oxide-releasing diazeniumdiolate (“Nitrosohydroxylamine”) functional group and its oxygen-substituted derivatives. Chem. Rev. 102, 1135–1154.
Hulsman, N., Medema, J.P., Bos, C., Jongejan, A., Leurs, R., Smit, M.J., de Esch, I.J.P., Richel, D., and Wijtmans, M. (2007). Chemical insights in the concept of hybrid drugs: The antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin. J. Med. Chem. 50, 2424–2431.
Ignarro, L.J. (1999). Nitric oxide: A unique endogenous signaling molecule in vascular biology (Nobel Lecture). Angew. Chem. Intd. Ed. 38, 1882–1892.
Ignarro, L.J. and Gruetter, C.A. (1980). Requirement of thiols for activation of coronary arterial guanylate cyclase by glyceryl trinitrate and sodium nitrite: Possible involvement of S-nitrosothiols. Biochim. Biophys. Acta 63, 221–231.
Jaffe, B.M. (1974). Prostaglandins and cancer: An update. prostaglandins 6, 453–461.
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., and Thun, M.J. (2008). Cancer statistics, 2008. CA Cancer J. Clin. 58, 71–96.
Ji, X., Pal, A., Kalathur, R., Hu, X., Gu, Y., Saavedra, J.E., Buzard, G.S., Srinivasan, A., Keefer, L.K., and Singh, S.V. (2008). Structure-based design of anticancer prodrug Paba/No. Drug Des. Dev. Ther. 2, 123–130.
Keefer, L.K. (2003). Progress toward clinical application of the nitric oxide-releasing diazeniumdiolates. Annu. Rev. Pharmacol. Toxicol. 43, 585–607.
Keefer, L.K. (2005). Nitric Oxide (No)− and Nitroxyl (Hno)− generating diazeniumdiolates (Nonoates): Emerging commercial opportunities. Curr. Top. Med. Chem. 5, 625–636.
Keefer, L.K., Nims, R.W., Davies, K.M., Wink, D.A., and Lester, P. (1996). “Nonoates” (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: Convenient nitric oxide dosage forms, methods in enzymology (Vol., 268, pp. 281–293). (ed.). Academic Press.
King, S.B. (2005). N-hydroxyurea and acyl nitroso compounds as nitroxyl (Hno) and nitric oxide (No) donors. Curr. Top. Med. Chem. 5, 665–673.
Kirilyuk, I.A., Utepbergenov, D.I., Mazhukin, D.G., Fechner, K., Mertsch, K., Khramtsov, V.V., Blasig, I.E., and Haseloff, R.F. (1998). Thiol-induced nitric oxide release from 3-halogeno-3,4-dihydrodiazete 1,2-dioxides. J. Med. Chem. 41, 1027–1033.
Kitagaki, J., Yang, Y., Saavedra, J.E., Colburn, N.H., Keefer, L.K., and Perantoni, A.O. (2008). Nitric oxide prodrug Js-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type P53. Oncogene 28, 619–624.
Kitagawa, H., Takeda, F., and Kohei, H. (1990). Effect of endothelium-derived relaxing factor on the gastric lesion induced by Hcl in rats. J. Pharmacol. Exp. Ther. 253, 1133–1137.
Kiziltepe, T., Hideshima, T., Ishitsuka, K., Ocio, E.M., Raje, N., Catley, L., Li, C.-Q., Trudel, L.J., Yasui, H., Vallet, S., Kutok, J.L., Chauhan, D., Mitsiades, C.S., Saavedra, J.E., Wogan, G.N., Keefer, L.K., Shami, P.J., and Anderson, K.C. (2007). Js-K, a Gst-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Blood 110, 709–718.
Kleschyov, A.L., Oelze, M., Daiber, A., Huang, Y., Mollnau, H., Schulz, E., Sydow, K., Fichtlscherer, B., Mulsch, A., and Munzel, T. (2003). Does nitric oxide mediate the vasodilator activity of nitroglycerin? Circ. Res. 93, e104–112.
Lehmann, J. (2000). Nitric oxide donors – Current trends in therapeutic applications. Expert Opin. Ther. Patents 10, 559–574.
Li, C.-Q., Trudel, L.J., and Wogan, G.N. (2002). Genotoxicity, mitochondrial damage, and apoptosis in human lymphoblastoid cells exposed to peroxynitrite generated from Sin-1. Chem. Res. Toxicol. 15, 527–535.
Lopez-Belmonte, J., Whittle, B.J., and Moncada, S. (1993). The actions of nitric oxide donors in the prevention or induction of injury to the rat gastric mucosa. Br. J. Pharmacol. 108, 73–78.
Lucas, L.T., Gatehouse, D., Jones, G.D.D., and Shuker, D.E.G. (2001). Characterization of DNA damage at purine residues in oligonucleotides and calf thymus DNA induced by the mutagen 1-nitrosoindole-3-acetonitrile. Chem. Res. Toxicol. 14, 158–164.
Lucas, L.T., Gatehouse, D., and Shuker, D.E.G. (1999). Efficient nitroso group transfer from N-nitrosoindoles to nucleotides and 2'-deoxyguanosine at physiological Ph. A new pathway for N-nitrosocompounds to Exert genotoxicity. J. Biol. Chem. 274, 18319–18326.
MacNaughton, W.K., Cirino, G., and Wallace, J.L. (1989). Endothelium-derived relaxing factor (Nitric Oxide) has protective actions in the stomach. Life Sci. 45, 1869–1876.
Malet-Martino, M., Jolimaitre, P., and Martino, R. (2002). The prodrugs of 5-fluorouracil. Curr. Med. Chem. Anticancer Agents 2, 267–310.
Manabe, T., Yamamoto, A., Satoh, K., and Ichihara, K. (2001). Tolerance to nitroglycerin induced by isosorbide-5-mononitrate infusion in vivo. Biol. Pharm. Bull. 24, 1370–1372.
Maragos, C.M., Andrews, A.W., Keefer, L.K., and Elespuru, R.K. (1993). Mutagenicity of glyceryl trinitrate (Nitroglycerin) in Salmonella Typhimurium. Mutat. Res. 298, 187–195.
Maragos, C.M., Morley, D., Wink, D.A., Dunams, T.M., Saavedra, J.E., Hoffman, A., Bove, A.A., Isaac, L., Hrabie, J.A., and Keefer, L.K. (1991). Complexes of no· with nucleophiles as agents for the controlled biological release of nitric oxide. Vasorelaxant effects. J. Med. Chem. 34, 3242–3247.
Martínez, A., Urios, A., Felipo, V., and Blanco, M. (2001). Mutagenicity of nitric oxide-releasing compounds in Escherichia Coli: Effect of superoxide generation and evidence for two mutagenic mechanisms. Mutat. Res. 49, 159–167.
Medana, C., Di Stilo, A., Visentin, S., Fruttero, R., Gasco, A., Ghigo, D., and Bosia, A. (1999). No donor and biological properties of different benzofuroxans. Pharm. Res. 16, 956–960.
Medana, C., Ermondi, G., Fruttero, R., Di Stilo, A., Ferretti, C., and Gasco, A. (1994). Furoxans as nitric oxide donors. 4-phenyl-3-furoxan carbonitrile: Thiol-mediated nitric oxide release and biological evaluation. J. Med. Chem. 37, 4412–4416.
Mellanen, P., Minn, H., Greman, R., and Harkonen, P. (1994). Expression of glucose transporters in head and neck tumors. Int. J. Cancer 56, 622–629.
Mijatovic, S., Maksimovic-Ivanic, D., Mojic, M., Malaponte, G., Libra, M., Cardile, V., Miljkovic, D., Harhaji, L., Dabideen, D., Cheng, K.F., Bevelacqua, Y., Donia, M., Garotta, G., Al-Abed, Y., Stosic-Grujicic, S., and Nicoletti, F. (2008). Novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide (Git-27no) induces P53 mediated apoptosis in human A375 melanoma cells. Nitric Oxide 19, 177–183.
Miranda, K.M., Nagasawa, H.T., and Toscano, J.P. (2005). Donors of Hno. Curr. Top. Med. Chem. 5, 649–664.
Mitchell, J.A., Akarasereenont, P., Thiemermann, C., Flower, R.J., and Vane, J.R. (1993). Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. USA 90, 11693–11697.
Moharram, S., Zhou, A., Wiebe, L.I., and Knaus, E.E. (2004). Design and synthesis of 3'- and 5'-O-(3-benzenesulfonylfuroxan-4-Yl)-2'-deoxyuridines: Biological evaluation as hybrid nitric oxide donor-nucleoside anticancer agents. J. Med. Chem. 47, 1840–1846.
Murad, F. (1999). Discovery of some of the biological effects of nitric oxide and its role in cell signaling (Nobel Lecture). Angew. Chem. Intd. Ed. 38, 1856–1868.
Myers, J.K. and Widlanski, T.S. (1993). Mechanism-based inactivation of prostatic acid phosphatase. Science 262, 1451–1453.
Nicolaus, B.J.R. (1983). Symbiotic approach to drug design, decision making in drug research. In Gross, F. (ed.). New York, NY, Raven Press.
Nicolescu, A.C., Li, Q., Brown, L., and Thatcher, G.R.J. (2006). Nitroxidation, nitration, and oxidation of a bodipy fluorophore by RNOS and Ros. Nitric Oxide 15, 163–176.
Núñez, C., Victor, V.M., Tur, R., Alvarez-Barrientos, A., Moncada, S., Esplugues, J.V., and D’Ocón, P. (2005). Discrepancies between nitroglycerin and No-releasing drugs on mitochondrial oxygen consumption, vasoactivity, and the release of No. Circ. Res. 97, 1063–1069.
O’Brien, M., Kruh, G.D., and Tew, K.D. (2000). The influence of coordinate overexpression of glutathione phase Ii detoxification gene products on drug resistance. J. Pharmacol. Exp. Ther. 294, 480–487.
Oh, S.M.N.Y.F. and Williams, D.L.H. (1989). Mechanism of S-nitrosation of cysteine derivatives in the Ph range 6–12 using N-methyl-N-nitrosotoluene-P-sulphonamide. J. Chem. Soc. Perkin Trans. 2, 755–758.
Parkin, D.M., Bray, F., Ferlay, J., and Pisani, P. (2005). Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74–108.
Ramirez, J., Yu, L., Li, J., Braunschweiger, P.G., and Wang, P.G. (1996). Glyco-S-nitrosothiols, a novel class of No donor compounds. Bioorg. Med. Chem. Lett. 6, 2575–2580.
Ren, Z., Kar, S., Wang, Z., Wang, M., Saavedra, J.E., and Carr, B.I. (2003). Js-K, a novel non-ionic diazeniumdiolate derivative, Inhibits Hep 3b hepatoma cell growth and induces C-Jun phosphorylation via multiple map kinase pathways. J. Cell Physiol. 197, 426–434.
Rigas, B. (2007). Novel agents for cancer prevention based on nitric oxide. Biochem. Soc. Trans. 35, 1364–1368.
Rigas, B. and Kozoni, V. (2008). The novel phenylester anticancer compounds: Study of a derivative of aspirin (Phoshoaspirin). Int. J. Oncol. 32, 97–100.
Rigas, B. and Williams, J.L. (2008). No-donating nsaids and cancer: An overview with a note on whether No is required for their action. Nitric Oxide 19, 199–204.
Rosenberg, L., Louik, C., and Shapiro, S. (1998). Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma. Cancer 82, 2326–2333.
Saavedra, J.E., Dunams, T.M., Flippen-Anderson, J.L., and Keefer, L.K. (1992). Secondary amine/nitric oxide complex ions, R2n[N(O)No]-O-functionalization chemistry. J. Org. Chem. 57, 6134–6138.
Saavedra, J.E., Srinivasan, A., Bonifant, C.L., Chu, J., Shanklin, A.P., Flippen-Anderson, J.L., Rice, W.G., Turpin, J.A., Davies, K.M., and Keefer, L.K. (2001). The secondary amine/nitric oxide complex ion R2n[N(O)No]- as nucleophile and leaving group in Snar reactions. J. Org. Chem. 66, 3090–3098.
Sako, M., Oda, S., Ohara, S., Hirota, K., and Maki, Y. (1998). Facile synthesis and NO-generating property of 4H-[1,2,5]Oxadiazolo[3,4-d]pyrimidine-5,7-dione 1-oxides. J. Org. Chem. 63, 6947–6951.
Schmutte, C., Rideout, W.M., III, Shen, J.-C., and Jones, P.A. (1994). Mutagenicity of nitric oxide is not caused by deamination of cytosine or 5-methylcytosine in double-stranded DNA. Carcinogenesis 15, 2899–2903.
Severina, I.S., Belushkina, N.N., and Grigoryev, N.B. (1994). Inhibition of Adp-induced human platelet aggregation by a new class of soluble guanylate cyclase activators capable of nitric oxide generation. Biochem. Mol. Biol. Int. 33, 957–967.
Severina, I.S., Bussygina, O.G., Vinograd, L.H., and Grigoryev, N.B. (1996). Mechanism of activation of soluble guanylate cyclase by guanidine thiols – A new class of enzyme activators. Biochem. Mol. Biol. Int. 38, 509–518.
Shami, P.J., Saavedra, J.E., Bonifant, C.L., Chu, J., Udupi, V., Malaviya, S., Carr, B.I., Kar, S., Wang, M., Jia, L., Ji, X., and Keefer, L.K. (2006). Antitumor activity of Js-K [O 2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-Yl]diazen-1-ium-1,2-diolate] and related O 2-aryl diazeniumdiolates in vitro and in vivo. J. Med. Chem. 49, 4356–4366.
Shami, P.J., Saavedra, J.E., Wang, L.Y., Bonifant, C.L., Diwan, B.A., Singh, S.V., Gu, Y., Fox, S.D., Buzard, G.S., Citro, M.L., Waterhouse, D.J., Davies, K.M., Ji, X., and Keefer, L.K. (2003). Js-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity. Mol. Cancer Ther. 2, 409–417.
Singh, R.J., Hogg, N., Joseph, J., and Kalyanaraman, B. (1996). Mechanism of nitric oxide release from S-nitrosothiols. J. Biol. Chem. 271, 18596–18603.
Sorba, G., Medana, C., Fruttero, R., Cena, C., Di Stilo, A., Galli, U., and Gasco, A. (1997). Water soluble furoxan derivatives as No prodrugs. J. Med. Chem. 40, 463–469.
Stauch, M., Grossmann, G., Wanjura, D., and Adam, W.E. (1990). Lack of tolerance after chronic administration of controlled-release isosorbide-5-mononitrate. Eur. J. Clin. Pharmacol. 38, 31–34.
Stuart, K.L. (1975). Furazans. Heterocycles 3, 651–690.
Sun, Y., Chen, J., and Rigas, B. (2009). Chemopreventive agents induce oxidative stress in cancer cells leading to cox-2 overexpression and cox-2-independent cell death. Carcinogenesis 30, 93–100.
Tew, K.D. and Gate, L. (2001). Glutathione S-transferases as emerging therapeutic targets. Expert Opin. Ther. Targets 5, 477–489.
Thadani, U., Maranda, C.R., Amsterdam, E., Spaccavento, L., Friedman, R.G., Chernoff, R., Zellner, S., Gorwit, J., and Hinderaker, P.H. (1994). Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate. Ann. Intern. Med. 120, 353–359.
Thatcher, G.R.J. (2007). Organic nitrates and nitrites as stores of No, radicals for life: The various forms of nitric oxide. In van Fassen, E., and Vanin, A. (ed.). Amsterdam, Elsevier.
Thatcher, G.R.J., Nicolescu, A., Reynolds, J.N., Zavorin, S.S., and Toader, V. (2001). Inhibition of lipid peroxidation by nitrates and nitrites. 222nd ACS National Meeting. Chicago, IL, United States, August 26–30, 2001. Abstracts of Papers TOX-022.
Thatcher, G.R.J., Nicolescu, A.C., Bennett, B.M., and Toader, V. (2004). Nitrates and No release: Contemporary aspects in biological and medicinal chemistry. Free Radical Biol. Med. 37, 1122–1143.
Townsend, D.M. and Tew, K.D. (2003a). Cancer drugs, genetic variation and the glutathione-S-transferase gene family. Am. J. Pharmacogeno. 3, 157–172.
Townsend, D.M. and Tew, K.D. (2003b). The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22, 7369–7375.
Turella, P., Cerella, C., Filomeni, G., Bullo, A., De Maria, F., Ghibelli, L., Ciriolo, M.R., Cianfriglia, M., Mattei, M., Federici, G., Ricci, G., and Caccuri, A.M. (2005). Proapoptotic activity of new glutathione S-transferase inhibitors. Cancer Res. 65, 3751–3761.
Turnbull, C., Marcarino, P., Sheldrake, T., Lazzarato, L., Cena, C., Fruttero, R., Gasco, A., Fox, S., Megson, I., and Rossi, A. (2008). A novel hybrid aspirin-No-releasing compound inhibits Tnf-a release from Lps-activated human monocytes and macrophages. J. Inflamm. 5, 12.
Udupi, V., Yu, M., Malaviya, S., Saavedra, J.E., and Shami, P.J. (2006). Js-K, a nitric oxide prodrug, induces cytochrome C release and caspase activation in Hl-60 myeloid leukemia cells. Leuk. Res. 30, 1279–1283.
Wallace, J.L., McKnight, W., Soldato, P.D., Baydoun, A.R., and Cirino, G. (1995). Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. J. Clin. Invest. 96, 2711–2718.
Wang, P.G., Xian, M., Tang, X., Wu, X., Wen, Z., Cai, T., and Janczuk, A.J. (2002). Nitric oxide donors: Chemical activities and biological applications. Chem. Rev. 102, 1091–1134.
Wermuth, C.G. (ed.) (2003). Designing Prodrugs and Bioprecursors. Practice of Medicinal Chemistry. Academic, London.
Whitehouse, M.W. and Ghosh, P.B. (1968). 4-nitrobenzofurazans and 4-nitrobenzofuroxans: A new class of thiol-neutralising agents and potent inhibitors of nucleic acid synthesis in leucocytes. Biochem. Pharmacol. 17, 158–161.
Williams, D.L.H. (1985). S-nitrosation and the reactions of S-nitroso compounds. Chem. Soc. Rev. 14, 171–196.
Williams, J.L., Borgo, S., Hasan, I., Castillo, E., Traganos, F., and Rigas, B. (2001). Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (Nsaids) alter the kinetics of human colon cancer cell lines more effectively than traditional Nsaids: Implications for colon cancer chemoprevention. Cancer Res. 61, 3285–3289.
Wink, D.A. and Mitchell, J.B. (2003). Nitric oxide and cancer: An introduction. Free Radical Biol. Med. 34, 951–954.
Wink, D.A., Vodovotz, Y., Laval, J., Laval, F., Dewhirst, M.W., and Mitchell, J.B. (1998). The multifaceted roles of nitric oxide in cancer. Carcinogenesis 19, 711–721.
Wolfe, M.M., Lichtenstein, D.R., and Singh, G. (1999). Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 340, 1888–1899.
Zavorin, S.I., Artz, J.D., Dumitrascu, A., Nicolescu, A., Scutaru, D., Smith, S.V., and Thatcher, G.R.J. (2001). Nitrate esters as nitric oxide donors: Ss-nitrates. Org. Lett. 3, 1113–1116.
Zhao, W., Mackenzie, G.G., Murray, O.T., Zhang, Z., and Rigas, B. (2009). Phosphoaspirin (Mdc-43), a novel benzyl ester of aspirin, inhibits the growth of human cancer cell lines more potently than aspirin: A redox-dependent effect. Carcinogenesis 30, 512–519.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science + Business Media, LLC
About this chapter
Cite this chapter
Anand, S., Thatcher, G.R.J. (2010). Nitric Oxide-Releasing Molecules for Cancer Therapy and Chemoprevention. In: Bonavida, B. (eds) Nitric Oxide (NO) and Cancer. Cancer Drug Discovery and Development. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-1432-3_20
Download citation
DOI: https://doi.org/10.1007/978-1-4419-1432-3_20
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-1431-6
Online ISBN: 978-1-4419-1432-3
eBook Packages: MedicineMedicine (R0)